A Pilot Study Evaluating the Usability of the Oabi Mobile Application
NCT04534946 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35
Last updated 2020-09-01
Summary
Our primary purpose is to assess the use feasibility and acceptability of the study phone app called, "Oabi" app with patients diagnosed with overactive bladder disorder (OAB).
Conditions
Interventions
- OTHER
-
This is not an intervention study
This is not an intervention study
Sponsors & Collaborators
-
Astellas Pharma Inc
collaborator INDUSTRY -
Massachusetts General Hospital
lead OTHER
Principal Investigators
-
Kamal Jethwani, MD · Massachusetts General Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-03-20
- Primary Completion
- 2019-03-31
- Completion
- 2019-12-31
Countries
- United States
Study Locations
More Related Trials
-
Evaluating a Digital Intervention for Overactive Bladder
NCT05170100 ·Status: COMPLETED ·Phase: NA
-
A Study of YM178 in Patients With Symptomatic Overactive Bladder
NCT00527033 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication
NCT01317810 ·Status: WITHDRAWN
-
A Study of YM178 in Subjects With Symptoms of Overactive Bladder
NCT01043666 ·Status: COMPLETED ·Phase: PHASE3
-
Validation of a Real-time Urodynamic Measure of Urinary Urgency
NCT00909428 ·Status: COMPLETED ·Phase: PHASE4
-
Reproducibility Study of Overactive Bladder Symptom Score [OABSS]
NCT01122550 ·Status: COMPLETED
-
Reproducibility Study of OABSS and Its Response to Treatment
NCT02667470 ·Status: COMPLETED ·Phase: PHASE4
-
A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients
NCT00840645 ·Status: COMPLETED ·Phase: PHASE3
-
A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)
NCT00454896 ·Status: COMPLETED ·Phase: PHASE3
-
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
NCT02386072 ·Status: COMPLETED
-
Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections
NCT07025044 ·Status: RECRUITING
-
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
NCT00350636 ·Status: COMPLETED ·Phase: PHASE3
-
Overactive Bladder Telemedicine Non-inferiority Trial
NCT05117918 ·Status: COMPLETED ·Phase: NA
-
Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome
NCT00313924 ·Status: UNKNOWN ·Phase: PHASE4
-
A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
NCT02320773 ·Status: COMPLETED
-
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00912964 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
NCT00966004 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00688688 ·Status: COMPLETED ·Phase: PHASE3
-
OnabotulinumtoxinA Bladder Injection Study
NCT03523091 ·Status: TERMINATED ·Phase: PHASE4
-
Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency
NCT01294982 ·Status: COMPLETED ·Phase: PHASE2
-
Reproducibility Study of Over Active Bladder Symptom Score [OABSS]
NCT00901251 ·Status: COMPLETED
-
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
NCT01093534 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of the Overactive Bladder Syndrome: A Delphi Study
NCT04300400 ·Status: COMPLETED
-
Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
NCT03044912 ·Status: UNKNOWN ·Phase: PHASE3
-
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
NCT00742833 ·Status: COMPLETED ·Phase: PHASE2